Modified Head and Neck Swallow Scale: Using EORTC-QLQ-H&N35 to Predict Overall Survival.

Modified Head and Neck Swallow Scale: Using EORTC-QLQ-H&N35 to Predict Overall Survival.
复制标题

改良头颈吞咽量表:使用 EORTC-QLQ-H

DOI:
10.1002/lary.29559
复制
发表时间:
2021
期刊:
The Laryngoscope
影响因子:
--
通讯作者:
Howell,RebeccaJ
Howell,RebeccaJ
中科院分区:
--
文献类型:
--
作者:
vonAllmen,Douglas;Tang,Alice;Takiar,Vinita;Zender,Chad;Romeo,Stephen;Masch,Jessica;Casper,Keith;Patil,Yash;Wilson,Keith;Khosla,Siddarth;Niu,Liang;Altaye,Mekibib;Tabangin,Meredith;Howell,RebeccaJ

文献摘要

相似文献

目的/假设吞咽困难是头颈癌(HNCA)的治疗相关并发症。我们证明了改良头颈吞咽量表(m-HNSW)的预测价值,该量表改编自欧洲癌症研究与治疗组织生活质量问卷-头颈部35(EORTC-QLQ-H&N35)。研究设计回顾性队列研究。方法回顾性单中心队列研究,利用前瞻性收集的高容量三级转诊中心HNCA患者数据库。确定了736例完成治疗后超过2年的HNCA患者。使用了从三个定义的护理事件中的至少一个收集的EORTC-QLQ-H&N35数据。m-HNSW使用三个问题形成9分吞咽困难量表。一个考克斯比例风险模型被用来确定影响的m-HNSW,同时控制人口统计学,肿瘤分期,网站,和treatment.ResultsUsing数据从3,6,12个月的治疗,我们分析了一个子集,包括328例患者。治疗结束后3个月,考虑体重指数后,m-HNSW评分与1年生存率(HR = 1.24,P = .0005)和5年生存率(HR = 1.19,P = .0002)显著相关。完成治疗后6个月(HR = 1.14,P = 0.014)和12个月(风险比(HR)= 1.33,P <0.0001)评分预测5年生存率。m-HNSW评分增加1分与死亡率增加24%相关,治疗后1年和5年死亡率增加19%。结论m-HNSW是使用先前验证的EORTC-QLC-H&N35数据对吞咽困难进行的简单评估,当在治疗完成后3个月、6个月和12个月进行评估时,可预测总生存率。证据等级4喉镜,131:2478-2482,2021
Objectives/HypothesisDysphagia is a treatment‐related complication of head and neck cancer (HNCA). We demonstrate the predictive value of a modified head and neck swallow scale (m‐HNSW) adapted from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Head and Neck 35 (EORTC‐QLQ‐H&N35).Study DesignRetrospective Cohort Study.MethodsRetrospective, single‐center cohort study utilizing a prospectively collected database of HNCA patients in a high‐volume tertiary referral center. 736 HNCA patients more than 2 years from completion of treatment were identified. EORTC‐QLQ‐H&N35 data collected from at least one of three defined episodes of care were used. The m‐HNSW uses three questions to form a 9‐point dysphagia scale. A Cox proportional hazards model was used to determine the effect of the m‐HNSW while controlling for demographics, tumor staging, site, and treatment.ResultsUsing data from 3, 6, 12 months from treatment, we analyzed a subset that included 328 patients. Three months after the completion of therapy, the m‐HNSW score had a significant association with 1 (HR = 1.24,P= .0005) and 5 year survival (HR = 1.19,P= .0002) after accounting for body mass index. Six (HR = 1.14,P= .014) and 12 month (hazard ratio (HR) = 1.33,P< .0001) scores post completion of therapy predict 5‐year survival. An increase of the m‐HNSW score by 1 point was associated with an increase in death by 24%, and 19% at 1 and 5 years following therapy.ConclusionsThe m‐HNSW is a simple assessment of dysphagia using previously validated EORTC‐QLC‐H&N35 data that when taken at 3, 6, and 12 months after completion of therapy is predictive of overall survival.Level of Evidence4Laryngoscope, 131:2478–2482, 2021